1236303-15-3

Basic information

• Product Name: 2,6-Dimethoxy-4-trifluoromethyl-benzoic acid
• Synonyms: 2,6-Dimethoxy-4-trifluoromethyl-benzoic acid
• CAS NO: 1236303-15-3
• Molecular Weight: 250.174
• Mol File: 1236303-15-3.mol

Chemical Properties

• CAS DataBase Reference: 2,6-Dimethoxy-4-trifluoromethyl-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dimethoxy-4-trifluoromethyl-benzoic acid(1236303-15-3)
• EPA Substance Registry System: 2,6-Dimethoxy-4-trifluoromethyl-benzoic acid(1236303-15-3)

Safety Data

• Hazardous Substances Data: 1236303-15-3(Hazardous Substances Data)

Upstream product

• 51271-36-4 2,6-dimethoxy-4-trifluoromethyl-benzonitrile 
• 7782-78-7 nitrosylsulfuric acid 
• 1466-76-8 2-6-dimethoxybenzoic acid 
• 2926-29-6 Langlois reagent 

Downstream Products

• 1352447-76-7 2-methoxy-6-methyl-4-trifluoromethyl-benzoic acid 2-methyl-2-nitro-propyl ester 
• 1316831-23-8 2-methoxy-6-methyl-4-trifluoromethyl-1-benzoic acid 
• 1268726-44-8 2-(2,6-dimethyl-4-trifluoromethyl-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 1268726-45-9 2-(2-Methoxy-6-methyl-4-trifluoromethyl-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 1268726-47-1 2,6-Dimethyl-4-trifluoromethyl-benzoic acid 2-methyl-2-nitro-propyl ester 
• 1268726-40-4 2,6-dimethyl-4-(trifluoromethyl)benzoic acid 
• 1268726-43-7 2-(2,6-dimethoxy-4-trifluoromethyl-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole 
• 1268726-42-6 N-(2-hydroxy-1,1-dimethyl-ethyl)-2,6-dimethoxy-4-trifluoromethyl-benzamide 

Relevant articles and documents

Catalyst-free direct C-H trifluoromethylation of arenes in water-acetonitrile

We describe a mild and practical strategy for the catalyst-free trifluoromethylation of arenes using the inexpensive solid sodium triflinate (Langlois' reagent, NaSO2CF3) as a trifluoromethyl (CF3) source and solid sodium

TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES

The present invention relates to a compound of general formula (I) wherein X is -O- or -CH2-; X' is -O- or -CH2-; with the proviso that one of X or X' is always -O- and the other is -CH2-.It has been found that the compoun

CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS

The present invention relates to the use of a compound of formula I wherein R1, R2, R3, R4, X and n are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS

The present invention relates to the use of a compound of general formula (I) wherein R1/R2 are independently from each other hydrogen, lower alkyl, -CH2)o-cycloalkyl for o being 0 or 1, or are benzyl or heterocycloalkyl; or R1 and R2 are together with the N-atom to which they are attached a ring containing -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)2-O-(CH2)2-, -(CH2)2-S-(CH2)2-, -(CH2)2-NR-(CH2)2-, -(CH2)2-C(O)-(CH2)2-, -(CH2)2-CF2-(CH2)2-, -CH2-CHR-(CH2)2, -CHR-(CH2)3, CHR-(CH2)2-CHR-, or is the ring 2,6-diaza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester and R is hydroxy, halogen, cycloalkyl, or C(O)O-lower alkyl; X is -(CH2)4-, -(CH2)3-, -(CH2)2- or -CH2-; R3 is S-lower alkyl, CF3, OCHF2, lower alkoxy, lower alkyl, phenyl, cycloalkyl or halogen; R4 is CF3, lower alkoxy, lower alkyl, halogen and n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers thereof for the manufacture of a medicament for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.

TETRAHYDRO-PYRAN DERIVATIVES

The present invention relates to a compound of formula I wherein R1/R2 are independently from each other hydrogen, (CR2)o-cycloalkyl, optionally substituted by lower alkyl or hydroxy, or are lower alkyl or heterocycloalkyl, and o is 0 or 1; andR may be the same or different and is hydrogen or lower alkyl; orR1 and R2 may form together with the N atom to which they are attached a heterocycloalkyl group, selected from the group consisting of pyrrolidinyl, piperidinyl, 3-aza-bicyclo[3.1.0]hex-3-yl or 2-aza-bicyclo[3.1.0]hex-2-yl, which are optionally substituted by hydroxy;R3 is S-lower alkyl, lower alkyl, lower alkoxy or cycloalkyl;R3′ is hydrogen, lower alkyl substituted by halogen, lower alkyl or lower alkoxyR4 is lower alkyl substituted by halogen, lower alkyl or lower alkoxy;X is —O— or —CH2—;X′ is —O— or —CH2—; with the proviso that one of X or X′ is always —O— and the other is —CH2—; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. It has been found that the compounds of formula I are good inhibitors of the glycine transporter 1 (GlyT-1) and therefore they may be used for the treatment of schizophrenia.

AMIDO-TROPANE DERIVATIVES

The present invention relates to a compound of formula I wherein R1, R2 and R3 are each independently hydrogen, lower alkyl, lower alkoxy, cycloalkyl, lower alkyl substituted by halogen or S-lower alkyl; or to a pharmaceut

AMIDO-TROPANE DERIVATIVES

The present invention relates to a compound of general formula (I) wherein R1, R2 and R3 are independently from each other hydrogen, lower alkyl, lower alkoxy, cycloalkyl, lower alkyl substituted by halogen or S-lower alky

PIPERIDINE DERIVATIVES

The present invention relates to a compound of formula I wherein R1, R2, and Ar are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical iso